Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07237282 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Jan 1, 2027 → Jul 1, 2027
See other at-risk trials from University of Alberta

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jan 1, 2027 to Jul 1, 2027 Show 4 more changesShow less
    • Start date: Aug 1, 2026 to Jan 15, 2027
    • Study completion pushed from Jul 1, 2027 to Jan 1, 2028
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: details revised at 1 of 3 entries
  2. Start date: Mar 1, 2026 to Aug 1, 2026v3
  3. Start date: Dec 1, 2025 to Mar 1, 2026v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to investigate the safety and antibody (germ fighters) response of the experimental (investigational) vaccine against HCV when injected into the arm of healthy adults.
Trial Details
NCT Number NCT07237282
Lead Sponsor University of Alberta
Conditions
(from sponsor)		 Hepatitis C
Related terms Hepatitis C
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov